Vg9Vd2 T cells play a major role as effector cells of innate immune responses against microbes, stressed cells, and tumor cells. They constitute ,5% of PBLs but can be expanded by zoledronic acid (ZA)-treated monocytes or dendritic cells (DC). Much less is known about their ability to act as cellular adjuvants bridging innate and adaptive immunity, especially in patients with cancer. We have addressed this issue in multiple myeloma (MM), a prototypic disease with several immune dysfunctions that also affect gd T cells and DC. ZA-treated MM DC were highly effective in activating autologous gd T cells, even in patients refractory to stimulation with ZA-treated monocytes. ZA inhibited the mevalonate pathway of MM DC and induced the intracellular accumulation and release into the supernatant of isopentenyl pyrophosphate, a selective gd T cell activator, in sufficient amounts to induce the proliferation of gd T cells. Immune responses against the tumor-associated Ag survivin (SRV) by MHC-restricted, SRV-specific CD8 + ab T cells were amplified by the concurrent activation of gd T cells driven by autologous DC copulsed with ZA and SRV-derived peptides. Ancillary to the isopentenyl pyrophosphate-induced gd T cell proliferation was the mevalonateindependent ZA ability to directly antagonize regulatory T cells and downregulate PD-L2 expression on the DC cell surface. In conclusion, ZA has multiple immune modulatory activities that allow MM DC to effectively handle the concurrent activation of gd T cells and MHC-restricted CD8 + ab antitumor effector T cells. The Journal of Immunology, 2011, 187: 1578-1590.
A key role is played by gd T cells in innate immune responses against microbes, stressed cells, and tumor cells (1) . Most circulating gd T cells use the same TCR V region pair Vg9-Vd2 (Vg9Vd2 T cells, hereinafter referred to as gd T cells) to sense the presence of infectious agents via the recognition of intermediate metabolites produced by the microbial nonmevalonate (non-Mev) pathway of isoprenoid synthesis (collectively termed phosphoantigens) (2, 3) . Synthetic phosphoantigen analogs, such as bromohydrin pyrophosphate (BrHPP), have been generated to selectively stimulate gd T cells and clinically exploit their effector functions against pathogens and tumor cells (4, 5) . The Mev pathway of mammalian cells also generates intermediate phosphorylated metabolites, such as isopentenyl pyrophosphate (IPP), which activate gd T cells as efficiently as their natural ligands (6, 7) . Cell stress and transformation increase Mev activity and accelerate the formation of intracellular phosphorylated metabolites, whose accumulation in excess of physiological levels is detected by gd T cells and renders the immune system able to sense potential threats such as stressed or transformed cells (6) . IPP levels are increased by drugs such as aminobisphosphonates (NBP) that selectively target farnesyl-pyrophosphate synthase (FPPS) in the Mev pathway (6) (7) (8) . When NBP are used to target the Mev pathway of professional APC, such as monocytes (MC) and dendritic cells (DC), a quick and robust proliferative expansion of gd T cells with antitumor activity is induced (9) (10) (11) .
gd T cells also act as cellular adjuvants bridging innate and adaptive immunity via mutual interactions with DC (12, 13) . We have shown in healthy individuals that MHC-restricted antiviral immune responses are improved by the concurrent activation of CD8 + ab T cells and gd T cells driven by autologous DC copulsed with zoledronic acid (ZA) and influenza virus-derived peptides (11) . Similar data have been reported in healthy individuals after copulsing DC with ZA and melanoma-derived peptides (14) .
Multiple myeloma (MM) is a disease with several immune dysfunctions that do not spare gd T cells and DC (9, (15) (16) (17) (18) (19) . Approximately 50% of MM patients at diagnosis have gd T cells refractory to stimulation with BrHPP or NBP mediated by MC (9, (15) (16) (17) . These patients are categorized as nonresponders (NR) and regarded as ineligible for gd T cell-based immune interventions (16). Cabillic et al. (20) have recently shown that gd T cell proliferation can be reinstated in NR patients with solid tumors using ZA-treated DC. However, MM DC are inclined to stimulate T cells with inhibitory functions (21, 22) , and whether they can reinstate gd T cell proliferation in NR patients, and effectively drive the concurrent activation of Ag-specific ab T cells and gd T cells, is an unanswered question not only in MM, but also in patients with cancer.
The aim of this work was: 1) to determine whether MM DC are as effective as normal DC in activating autologous gd T cells in both responders (R) and NR, and 2) to determine whether immune responses against tumor-associated Ags in MM can be amplified by the mutual interactions between gd T cells and MHC-restricted CD8 + ab T cells driven by autologous DC copulsed with ZA and survivin (SRV). SRV was selected as a prototypic tumorassociated Ag on account of its aberrant expression in MM and because SRV-specific cytotoxic CD8 + ab T cells are tolerized but not deleted from the MM T cell repertoire (23) .
Materials and Methods

Cells and reagents
Peripheral blood samples were drawn from MM at diagnosis only. Different series of experiments were performed on a total number of 22 patients. The controls (CTRL) were healthy blood donors kindly provided by the local Blood Bank (Fondazione Strumia). Samples were collected after informed consent and approval by the local Institutional Review Boards.
After isolation on a Ficoll-Hypaque density gradient, PBMC were kept unfractionated or further processed to purify CD14 + cells and generate different APC preparations. Aliquots of PBMC and CD14-depleted cells (i.e., PBL) were kept at 37˚C or frozen in liquid nitrogen to be subsequently used without further manipulation or as a source of T cells in coculture experiments with autologous APC.
The standard culture medium was RPMI 1640 (Euroclone, Milano, Italy), containing 10% FCS (Euroclone), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Flow cytometry
The following mAbs were used: anti-CD3, anti-CD8, anti-CD4, anti-CD25, anti-CD54 (Caltag Laboratories, Burlingame, CA); anti-pan-TCR gd, anti-TCR-Vg9, anti-TCR-ab, anti-CD56, anti-CD80, anti-HLA-DR (Becton Dickinson, San Jose, CA); anti-CD3, anti-CD14 (Dako SpA, Milano, Italy); anti-CD83 (BD Pharmingen International, San Diego, CA), anti-CD86 (Chemicon, Chandlers Ford, Hampshire, U.K.), anti-HLA-A2 (Proimmune, Oxford, U.K.); anti-CD1a, CD45RA (Valter Occhiena, Torino, Italy), anti-CD27 (Ancell, Byport, MN); anti-FOXP3, anti-CD279 (PD-1), anti-B7-H1 (PD-L1), and anti-B7-DC (PD-L2; eBioscience, San Diego, CA).
Two-and three-color flow cytometry were performed with the appropriate combinations of FITC, r-PE-(PE), Tricolor-(Tri), PerCP complex-(PerCP), or allophycocyanin-conjugated Abs, a FACScan cell sorter, and CellQuest software (Becton Dickinson, Mountain View, CA).
Regulatory T cell (Treg) cells were identified by incubation with PerCPconjugated anti-CD4 and PE-conjugated CD25 at 4˚C for 20 min in the dark. After washing, they were fixed and permeabilized at 4˚C for 40-60 min (according to the manufacturer's instructions), washed twice with permeabilization buffer, and then incubated at 4˚C in the dark for 30 min with 20 ml anti-Foxp3 FITC or isotype CTRL mAb. After washes with Perm/Wash buffer, cells were fixed with 250 ml 1% paraformaldehyde-PBS buffer.
Total counts of specific cell subsets per well were determined by multiplying total counts of viable cells per well by the percentage of cells of interest, the latter being identified by two-or three-color flow cytometry and appropriate gating.
APC generation
MC were purified using CD14 MicroBeads and LS columns (Miltenyi Biotec, Bologna, Italy), and incubated for 24 h in 24- ), as previously reported (11, 22) .
Fast DC (f-DC) were generated according to Dauer et al. (24) . Purified CD14 + cells were cultured in standard culture medium at 0.5-1.5 3 10 6 cells/ml supplemented with GM-CSF (1000 U/ml) and IL-4 (500 U/ml) in flat-bottom 6-well plates for 24 h. After washing, they were incubated for a further 24 h with IL-1b (10 ng/ml), TNF-a (1000 IU/ml), IL-6 (10 ng/ ml), and PGE 2 (1 mg/ml) in the presence (f-DC ZA+ ) or absence (f-DC ZA2 ) of 5 mM ZA.
APC were always washed before mixing with autologous PBL or T cells. In selected experiments, supernatants were collected for quantification of extracellular IPP levels and to investigate their ability to induce autologous gd T cell proliferation.
The internalization capability of iDC, mDC, and f-DC was tested by using FITC-conjugated dextran (FITC-dextran; 10 kDa; Sigma Aldrich, Milano, Italy).
gd T cell proliferation CTRL and MM patients were classed as R or NR according to their proliferative PBMC responses to 1 mM ZA + 10 IU/ml IL-2 (Eurocetus, Milan, Italy), as previously reported (9) .
Cryopreserved or freshly isolated PBL were added at the ratio of 5:1 to autologous iDC/mDC or MC/f-DC, respectively, and cultured at 1 3 10 6 / ml with 10 IU/ml IL-2. On day 7, percentages and total counts of viable gd T cells and Tregs were calculated with the trypan blue staining assay and by flow cytometry, as previously reported (11, 25) .
In selected experiments, PBMC and PBL from CTRL R were stimulated for 7 d with the supernatants obtained from autologous f-DC ZA2 and f-DC ZA+ and 10 IU/ml IL-2 to evaluate their ability to induce gd T cell proliferation.
Modulation of SRV-specific immune responses
The HLA-A*0201 + -restricted, SRV-derived peptide LMLGEFLKL (SRVp; Proimmune) was used to investigate MHC-restricted immune responses mediated by CD8 + ab T cells. iDC were generated from HLA-A*0201 + CTRL and MM, and left untreated or pulsed with 10 mM SRVp for 2 h at room temperature in serum-free medium. After washing, iDC maturation was induced in the presence or absence of 5 mM ZA as reported earlier. On the same day, CD3 + cells were purified from cryopreserved autologous PBMC (Miltenyi Pan T Cell Isolation Kit), mixed at the DC:T ratio of 1:10 in round-bottom plates, and incubated for 10 d in the presence of 10 IU/ml IL-2, replenished every 3 d. On day 10, T cells were restimulated for additional 10 d with a second batch of freshly generated mDC. On days 10 and 20, the frequency of SRV-specific CD8 + ab T cells was determined by flow cytometry with a commercially available PElabeled kit (Pro5 MHC Pentamer; Proimmune), according to the manufacturer's instructions. Because Pro5 Pentamers can bind nonspecifically to B cells, both CD8 and CD19 mAbs were added after pentamer staining, and a minimum number of 500,000 events was acquired after backgating on viable CD8 + CD19 2 cells. f-DC were also left untreated or pulsed with SRVp, and incubated with (f-DC ZA+ ) or without 5 mM ZA (f-DC ZA2 ) as reported earlier for mDC. CD3 + cells were purified from cryopreserved autologous PBMC and incubated for 14 d with f-DC at the DC:T ratio of 1:10 in round-bottom plates in the presence of 10 IU/ml IL-2 that was replenished every 3 d. One round of 14-d stimulation was used based on side-by-side experiments showing that it was equivalent to two rounds of 10-d stimulation (see later and Supplemental Fig. 4) .
The cytotoxic activity of CD8 + ab T cells was tested against the TAPdeficient, SRVp-loaded HLA-A2 + T2 cell line, the HLA-A2 + SRV + myeloma cell line RPMI 8226, and HLA-A2 + myeloma cells isolated from the peripheral blood of a plasma cell leukemia (PCL) patient, as previously reported (11) .
The specificity of anti-SRV immune responses was assessed by using the HLA-A2-restricted CMV-(NLVPMVATV; Proimmune) and HIV-derived (SLYNTVATL; Proimmune) peptides (CMVp, HIVp) to load f-DC ZA+ and f-DC
ZA2
, and by determining the frequency and total counts of viable CD8 + ab T cells specifically reacting against the SRVp, CMVp, and HIVp after 14-d stimulation.
mM NaVO 4 and centrifuged at 1200 3 g for 5 min at 4˚C. After lyophilization under vacuum, samples were resuspended in 20 ml dimethylhexylamine and separated by TLC. Gels were exposed to an iodine-saturated atmosphere for 2 h, spots corresponding to each isoprenoid species were isolated, and radioactivity uptake was measured by liquid scintillation counting (Ultima Gold; Perkin Elmer). The titration curves for each isoprenoids species were performed using three serial dilutions of PBMC. Treg function was assessed as previously described (28) . Allogenic PBMC were irradiated at 3000 rad and used as accessory cells, and 1 mg/ ml soluble anti-CD3 (OKT3 Orthoclone; Janssen-Cilag, Cologno Monzese, Italy) was used to induce polyclonal T cell activation. Tregs (CD4 
Statistical analysis
Results are expressed as mean values 6 SE. Differences between sample groups were evaluated with the two-tailed nonparametric Mann-Whitney U test for paired samples or with the Fisher exact test for unpaired data. Correlations were assessed by Pearson correlation coefficient. The significance cutoff value was p , 0.05. The p values are reported in the figures.
Results
mDC ZA+ are potent inducers of gd T cell proliferation irrespective of R/NR status
The first series of experiments was deliberately confined to CTRL and MM R to identify the most effective APC inducing gd T cell proliferation in a susceptible population. As expected, no significant proliferation of gd T cells was observed with IL-2 alone in the absence of ZA (Fig. 1 ). The highest gd T cell counts were observed after stimulation with ZA-treated mDC in both CTRL (p , 0.01) and MM (p , 0.3). MM (Fig. 1A , right panel) displayed significantly higher counts than CTRL (Fig. 1A , left panel) after stimulation with both ZA-treated MC (p , 0.05) and ZAtreated mDC (p , 0.005).
A significant increase of central memory (CM) and effector memory (EM) gd T cells was detected after stimulation with ZA +IL-2 versus IL-2 alone in CTRL and MM R (p , 0.05). In MM, CM and EM gd T cell counts were significantly higher than in CTRL after both IL-2 and ZA+IL-2 stimulation (both p , 0.05). CM was the predominant subset in CTRL R, whereas EM was predominant in MM R (Fig. 1B) .
Approximately 50% of MM patients at diagnosis display minimal or no gd T cell proliferation after PBMC stimulation with 1 mM ZA + 10 IU/ml IL-2 (NR). Less than 5% of our CTRL were NR. In view of the very effective gd T cell stimulatory capacity of mDC ZA+ , we performed a side-by-side experiment with PBMC ZA+ and MC ZA+ in the two NR groups. mDC ZA+ restored gd T cell proliferation in both groups (p , 0.0003; Fig. 1C ). Flow cytometry of gd T cells after stimulation with PBMC ZA+ and mDC ZA+ in one representative MM NR is shown in Fig. 1D .
Immunophenotyping showed that mDC ZA+ induced the expansion of gd T cells equipped with surface receptors to exert costimulatory (HLA-DR, CD86, CD80), but not inhibitory (PD-1, PD-L1), activity on immune responses (Fig. 1E ) in MM R and NR.
SRV-specific immune responses mediated by CD8
+ ab T cells are upregulated by the concurrent gd T cell proliferation
The baseline frequency of SRV-specific CD8 + ab T cells in the peripheral blood was significantly higher in MM than in CTRL (0.41 6 0.05 versus 0.07 6 0.03%; p , 0.0001; Supplemental Fig.  1 ). The frequency and total counts of SRV-specific CD8 + ab T cells was then investigated after stimulation with mDC SRVp2ZA2 , mDC SRVp2ZA+ , mDC SRVp+ZA2 , and mDC SRVp+ZA+ . Results from representative experiments in the CTRL and MM R and NR groups are shown in Fig. 2A and 2B, and the pooled data are shown in Fig.  2C . Given the equivalent gd T cell proliferation and number of CD8 + ab T cells induced by mDC ZA+ , R and NR individuals were grouped together in CTRL and MM. Total counts were significantly higher after stimulation with mDC SRVp+ZA+ compared with stimulation with mDC SRVp+ZA2 (p , 0.05 in both CTRL and MM), indicating that the concurrent activation of gd T cells and CD8 + ab T cells was not mutually detrimental.
The cytotoxic activity of SRV-specific CD8 + ab T cells was tested against the HLA-A2 + SRVp-pulsed T2 cell line (T2 SRVp+ ). As expected, the highest cytotoxicity was observed when T cells were stimulated with mDC SRVp+ZA+ in both CTRL and MM (p , 0.05 compared with cytotoxic values after stimulation with mDC SRVp+ZA2 in both groups) ( f-DC ZA+ are as effective as conventional mDC ZA+ in inducing gd T cell proliferation and upregulating SRV-specific immune responses
The production of conventional mDC is a time-consuming, laborintensive, and costly process that requires enough PBMC to generate the mDC needed for two rounds of stimulation. To overcome these limitations, we used f-DC ZA+ to stimulate autologous gd T cells. f-DC were generated in 48 h from CTRL and MM irrespective of their R/NR status. The immunophenotype and endocytic capacity of immature and mature before (f-DC ZA2 ) and after (f-DC ZA+ ) ZA treatment are shown in Supplemental Table I and Supplemental Fig. 3 . A side-by-side comparison in CTRL R between the ability of f-DC ZA+ and mDC ZA+ to stimulate autologous gd T cells and induce the expansion of SRV-specific CD8 + ab T cells is shown in Supplemental Fig. 4 . The total number of gd T cells was not statistically different either on day 10 (after one round) or 20 (after two rounds), whereas the number of SRVspecific CD8
+ ab T cells per well was even higher after stimulation with f-DC ZA+ . We also compared the total numbers of gd T cells and SRV-specific CD8 + ab T cells per well after two 10-d stimulations as opposed to only one of 14 d without detecting any difference (Supplemental Fig. 4 ). Based on these results, f-DC ZA+ were also used to stimulate gd T cells in MM patients. Indeed, they effectively induced the proliferative expansion of gd T cells in CTRL R and NR (p , 0.04 and p , 0.03, respectively), and in MM R and NR (both p , 0.04; Fig. 3A) . Flow cytometry of reinstated T cell proliferation in representative CTRL and MM NR are shown in Fig. 3B . f-DC ZA+ also amplified SRV-specific immune responses in both CTRL and MM R and NR. Flow cytometry of representative samples is shown in Fig. 3C and 3D . The specificity of MHC-restricted immune responses generated by the costimulation of gd T cells and CD8 + ab T cells is demonstrated in Fig. 3E . CTRL T cells were stimulated with f-DC ZA+ and f-DC ZA+ loaded or unloaded with the HLA-A2-restricted SRVp, CMVp, and HIVp. The frequency of specific CD8 + ab T cells was determined with the corresponding PE-labeled pentamers. As expected, only CD8 + ab T cells specific for the peptide used to load f-DC ZA2 and f-DC ZA+ were increased after 14-d incubation. Pooled data reporting total counts of SRV-specific CD8 + ab T cells and cytotoxicity against the RPMI 8226 myeloma cell line are shown in Fig. 3F and 3G, respectively. The most effective anti-SRV activity was observed after stimulation with f-DC SRVp+ZA+ in both CTRL and MM. Fig. 3H shows that CD8 + ab T cells elicited by f-DC SRVp+ZA+ are also able to recognize and kill primary myeloma cells. The specificity of this antitumor immune response is corroborated by the observation that T cells do not exert any cytotoxicity when CMVp is used to load f-DC.
Accelerated Mev activity in mDC and f-DC, and enhanced IPP production after ZA treatment
The ability of ZA-treated APC to activate cells is dependent on their capacity to inhibit FPPS in the Mev pathway (10) . We have compared the Mev activity rate in MC, mDC, and f-DC at baseline and after treatment with 5 mM ZA (i.e., the conditions used to stimulate T cells). Baseline cholesterol and both intracellular and extracellular IPP levels progressively increased from MC to f-DC, with mDC displaying intermediate values (Fig. 4) . Unexpectedly, extracellular IPP concentrations were 1000 times greater than the intracellular concentrations. ZA-induced FPPS inhibition decreased the production of cholesterol and FPP, and further in- creased intracellular and extracellular IPP levels. All differences were statistically different between untreated and ZA-treated cells. The most striking effect was the increase of extracellular IPP in the supernatants of f-DC to concentrations almost 10 times greater than those in the supernatants of ZA-treated MC and mDC.
To further demonstrate the key role played by the Mev pathway, mDC and f-DC were treated with ZA in the presence or absence of simvastatin (Sim). Sim prevents ZA-induced IPP accumulation by specifically inhibiting hydroxy-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the Mev pathway acting upstream from FPPS (29, 30) . As predicted (9, 22, 30) , Sim abrogated the ability of mDC ZA+ and f-DC ZA+ to induce the proliferation of gd T cells (data not shown; see also Figs. 5, 6).
The IPP released in the supernatants of f-DC ZA+ is sufficient to induce gd T cell proliferation PBMC and PBL from CTRL R were incubated for 7 d with the supernatants collected from f-DC ZA2 and f-DC ZA+ , and supplemented with 10 IU/ml IL-2. Final dilutions were 1, 10, and 20% corresponding to extracellular IPP concentrations of 14, 144, and 288 nM, respectively (Fig. 5B, left panel) . Standard cultures with IL-2 and ZA+IL-2 served as CTRL (Fig. 5A) . As expected, gd T cell proliferation was induced only in PBMC, because PBL are depleted of MC and cannot generate adequate IPP amounts to stimulate gd T cells (9, 10) . By contrast, gd T cell proliferation was equivalent in PBMC and PBL after incubation with f-DC ZA+ supernatants, indicating that the concentration of extracellular IPP was sufficient to induce gd T cell proliferation, even in the absence of MC, as previously reported for exogenous IPP (2). In confirmation, PBMC and PBL from CTRL R were stimulated with exogenous IPP at concentrations including those detected in f-DC ZA+ supernatants (from 14 to 280 nM; Fig. 5B , right panel). Exogenous IPP induced the proliferation of gd T cells, but with lower efficiency than f-DC ZA+ supernatants, especially if used in the presence of MC (PBMC versus PBL) and at concentrations equivalent to those of f-DC ZA+ supernatants (i.e., from 10 28 to 10 27 M). It also induced gd T cell proliferation in PBMC and PBL as effectively as f-DC ZA+ supernatants when used at higher concentrations (.10 26 M). These results suggest that other cytokines and/or growth factors may be present in f-DC ZA+ supernatants and promote gd T cell proliferation in association with the low endogenous IPP concentrations. It is also possible that MC preferentially use exogenous IPP to the disadvantage of gd T cells, because higher concentrations are required to induce gd T cell proliferation in PBMC versus PBL.
Extracellular IPP was also measured in the supernatants of f-DC ZA+ cultured in the presence or absence of Sim. As predicted, (Fig. 5C ) and the supernatant of f-DC ZA+Sim+ failed to induce any proliferation of gd T cells irrespective of whether MC were present in the responding population (Fig. 5D ).
Antagonism of ZA and gd T cells versus Tregs
gd T cell proliferation can be suppressed by Tregs (17, 31), and their excess over gd T cells has been proposed as an explanation for defective ZA-induced gd T cell proliferation in MM NR (17) . Treg and gd T cell counts and ratios were not significantly different in function of R/NR status in the peripheral blood of CTRL and MM patients (data not shown). We also looked for correlations in individual CTRL and MM R between baseline Treg and gd T cell values, and the increase of gd T cells after stimulation with ZA+IL-2. The only statistically significant finding was a direct correlation between baseline gd T cell counts and their fold increase after stimulation in CTRL R, whereas no correlation was detected with Tregs (data not shown).
Total counts of viable Tregs were also calculated after 7-d PBMC stimulation in the presence or absence of IL-2, ZA, or both (Fig. 6A) . These are the only culture conditions that discriminate between the R/NR status, which is no longer detectable after mDC ZA+ or f-DC ZA+ stimulation. IL-2 is a major Treg growth factor (32); therefore, their increase after incubation with 10 IU/ml IL-2 was expected. Notably, the increase was higher in MM R than in MM NR, which rules out enhanced Treg IL-2 reactivity in the latter. The increase was significantly blunted when ZA was added to IL-2 (ZA+IL-2 versus IL-2) in both MM R (p , 0.05) and NR (p , 0.05), even if gd T cell proliferation occurred in the former only. The fact that Treg counts were also higher after incubation in RPMI 1640 than after stimulation with ZA alone (p , 0.05 in both R and NR), a condition that does not lead to any gd T cell expansion even in MM R, provides further evidence that ZA re strains Treg expansion via gd T celldependent and -independent mechanisms. Flow cytometry of Treg after PBMC stimulation in representative MM R and NR is illustrated in Supplemental Fig. 5A . To further investigate the mechanisms exploited by ZA to antagonize Tregs independently of gd T cells, we tested the ability of Tregs to regulate the proliferation of autologous CD4 + CD25 2 driven by irradiated accessory cells and OKT3 in the presence or absence of ZA (Fig. 6B) that the ZA-induced anti-Treg activity did not require any gd T cell proliferation and was independent of the inhibition of the Mev pathway (Supplemental Fig. 5B, right panel) . Previous reports have shown that MM DC are inclined to stimulate T cells with inhibitory functions (21, 22) . Thus, Treg counts were evaluated in MM R and NR after stimulation with ZA-treated and untreated mDC and f-DC (Fig. 6C ). As expected, ZA induced the proliferation of gd T cells, and this was uniformly associated with lower Treg counts in both MM R and NR. To investigate whether ZA could also antagonize Tregs independently of gd T cell proliferation in these cultures, we evaluated Treg counts on day 7 after stimulation with f-DC ZA+ and f-DC ZA2 in the presence or absence of Sim. Sim alone had no effect on Tregs and did not impair the ability of ZA to antagonize Tregs (Fig. 6D , upper panels) even if Sim completely abrogated gd T cell proliferation (Fig. 6D, lower panels) . Altogether, these results indicate that ZA antagonizes Tregs independently of gd T cell proliferation and Mev pathway inhibition.
ZA downregulates PD-L2 expression in mDC and f-DC PD-L1 and PD-L2 expression was evaluated in MC, mDC, and f-DC under basal conditions and after ZA treatment. PD-L1 was constitutively expressed on MC, mDC, and f-DC, and its expression was not modified by ZA (data not shown, Fig. 7B ). PD-L2 was expressed by a smaller proportion of resting MC and was not changed after ZA treatment (Fig. 7A) . By contrast, PD-L2 was expressed by most mDC and f-DC under basal conditions, and this expression was significantly downmodulated by ZA in CTRL mDC (p , 0.001) and f-DC (p , 0.05), and MM mDC (p , 0.05; Fig. 7A ).
Sim alone had no effect on PD-L2 expression and did not prevent ZA-induced PD-L2 downregulation (Fig. 7B, upper row) . It also had no effect on the expression of PD-L1, whether alone or in association with ZA (Fig. 7B, lower row) . These data indicate that ZA modulates the cell surface immunophenotype of mDC and f-DC independently from the Mev pathway.
Inhibition of gd T cell expansion by Sim prevents the amplification of SRV-specific CD8 + ab T cells
The generation of SRV-specific CD8 + ab T cells after stimulation with mDC SRVp+ZA+ was evaluated in the absence or presence of Sim. As reported earlier, Sim prevented the IPP-dependent proliferation of gd T cells (Fig. 8A) , which, in turn, was associated with a failed amplification of SRV-specific CD8 + ab T cells ( very well recognized, and several studies are investigating the possibility of exploiting their effector properties in infections and cancer (1, 5) . Much less is known about their ability to act as cellular adjuvants bridging innate and adaptive immunity, especially in patients with cancer. We have addressed this issue in MM, a prototypic disease characterized by multiple immune dysfunctions that also involves gd T cells and DC (9, (15) (16) (17) (18) (19) .
The first series of experiments was deliberately confined to CTRL and MM R to identify the APC most capable of inducing the proliferation of autologous gd T cells. mDC ZA+ generated from MM R were even more efficient than their normal counterparts in inducing this proliferation. After 7-d stimulation, there was a preferential expansion of CM and EM gd T cells in MM R patients that was significantly greater than that observed in CTRL. By analogy with conventional CD8 + cells (33, 34) , CM gd T cells are credited as the preferred subset for adoptive immunotherapy because they have self-renewal capacity and more effective antitumor activity in vivo than terminally differentiated CD45RA + (TEMRA) cells, even though the latter are more potent in vitro (35) .
Approximately 50% of MM patients at diagnosis are classified as NR because gd-T cell proliferation is not detected after challenging PBMC for 7 d with ZA+IL-2 (9, (15) (16) (17) . A similar proportion has been reported in patients with other lymphoproliferative disorders and metastatic solid cancer (17) . gd T cells from MM NR produce IFN-g and exert cytotoxic activity against myeloma cells once activated by ZA+IL-2 (9), but NR patients are typically excluded from gd T cell-based adoptive immunotherapy trials because of the impossibility of increasing the number of cells and establishing a favorable E:T cell ratio in vivo or ex vivo.
In view of the high efficiency of mDC ZA+ , we tested their ability to induce gd T cell proliferation in CTRL and MM NR. Occasionally, healthy individuals (,5% in our experience) are also refractory to ZA stimulation. mDC ZA+ were very effective in both CTRL and MM NR, and resulted in the proliferative expansion of but also in those NR MM in which gd T cell proliferation was reinstated. SRV was selected as a prototypic tumor-associated Ag because it is expressed by myeloma cells and contributes to their survival (38) . SRV-specific T cells have been tolerized but not deleted from the MM T cell repertoire (23) , and their effector functions can be reinstated by appropriate SRV presentation and T cell stimulation (39, 40) . Moreover, SRV is also expressed by many other tumor cells of hematopoietic and epithelial origin (41) . The frequency of SRV-specific CD8 + ab T cells in the peripheral blood of MM was higher than in CTRL, suggesting a previous exposure and selective recruitment in the early phases of the disease. Their frequency was significantly enhanced in both CTRL and MM after stimulation with mDC SRVp+ZA+ , leading to enhanced cytotoxicity against the appropriate HLA*0201 + SRV + target cells irrespective of the initial R/NR status. These data The Journal of Immunologyindicate that mDC SRVp+ZA+ of CTRL and MM can handle the concurrent activation of autologous gd T cells and tumor-specific CD8 + ab T cells with a mutual edge on their immune performances. The final outcome of these reciprocally gainful interactions is the generation of a composite population of innate and adaptive antitumor effector cells, embodying both CM and EM gd T cells and CD8
+ ab T cells. The generation of conventional mDC ZA+ by standard protocols is a labor-intensive, time-consuming, and costly procedure that requires adequate cell inputs that, in turn, are dependent on sufficient blood samples. To corroborate the translational value of our findings, we conducted a subsequent series of experiments using DC generated according to an alternative protocol yielding mDC from CD14
+ cells within only 48 h of in vitro culture (f-DC) (24, 42) . This strategy has been adapted and validated for large-scale production under GMP conditions in patients with advanced prostate cancer (43) , but the ability of f-DC to induce the proliferation of gd T cells and concurrently activate MHC-restricted CD8 + ab T cells is unknown. We have shown that f-DC can be successfully generated from CD14 + cells in both CTRL and MM R and NR. (42) and Jarnjak-Jankovic et al. (43) have shown that 5-7 d are sufficient for f-DC to induce primary and secondary Agspecific T cell immune responses, and because the kinetics of SRV-specific CD8 + ab T cell expansion significantly increased from days 10 to 14, but not from days 14 to 20 (see also Fig. 8B , Supplemental Fig. 4) .
As stated earlier, gd T cells are activated by IPP, an intermediate Mev metabolite mimicking their natural ligands (6, (8) (9) (10) . Under basal conditions, the highest IPP production was observed in mDC and f-DC, the latter showing significantly higher values. As predicted, IPP concentrations further increased after ZA treatment, and the most striking increase was detected in the supernatants of f-DC ZA+ in which extracellular IPP concentrations were 10 times greater than those detected in MC ZA+ and mDC ZA+ supernatants. Unexpectedly, IPP concentrations in the supernatants were 1000 times greater than the intracellular ones. Thus, IPP is produced and released in the supernatant in sufficient amounts to induce gd T cell proliferation, even in the absence of MC. These results are in line with previous studies showing that gd T cell activation by exogenous IPP is TCR mediated and APC independent (2). We have also observed that exogenous IPP induces the proliferation of gd T cells, but with a lower efficiency than f-DC ZA+ supernatants, especially if used at low concentrations and in the presence of MC. So far, most studies have investigated the activity of IPP at high concentrations on purified gd T cells, gd T cell lines, or gd T cell clones, whereas few data are available for IPP at low concentrations on MC-containing populations. The lower efficiency of exogenous IPP compared with f-DC ZA+ supernatants, especially in PBMC, could reflect either an MC-mediated IPP sequestration to the disadvantage of gd T cells or the presence of additional soluble factors in f-DC ZA+ supernatants. Studies are currently in progress to address this issue.
The importance of IPP in f-DC ZA+ supernatants was confirmed by the experiments in which Sim was used as an irreversible and selective hydroxy-methylglutaryl-coenzyme A reductase inhibitor to prevent intracellular IPP accumulation (11, 30) , and its release in the supernatants. Indeed, Sim treatment blunted the proliferative activation of gd T cells induced by mDC ZA+ and f-DC ZA+ by setting almost to zero extracellular IPP concentrations. Activated gd T cells are enabled to behave as cellular adjuvants in several ways, including the expression of costimulatory receptors and appropriate cytokine production. The frequency of SRV-specific CD8 + ab T cells was uniformly higher in cultures in which gd T cells had proliferated, and this increase was mostly evident after gd T cells had become the predominant population. These data confirm previous results in healthy individuals indicating that gd T cell proliferation anticipates and is not detrimental to the subsequent increase of Ag-specific CD8 + ab T cells (11, 14) . Activated CM and EM gd T cells are enabled to behave as cellular adjuvants in several ways, including the expression of costimulatory receptors and the production of IFN-g, which promotes the functional maturation of DC and the development of antitumor cell-mediated immune responses (14, 23, 43, 44) . mDC ZA+ and f-DC ZA+ themselves may contribute to Th1 polarization, because we have previously shown that mDC ZA+ produce more IL-12 and less IL-6 compared with mDC ZA+ (11) . gd T cells antagonized the IL-2-induced proliferation of Tregs. Low-dose IL-2 is indispensable to sustain ZA-induced gd T cell proliferation, but it is also the main growth factor for Tregs (32) , and mDC from MM patients are intrinsically inclined to promote the growth of Tregs (21, 22 ). Our results demonstrate that gd T cell proliferation induced by PBMC ZA+ , mDC ZA+ , and f-DC We did not disclose major differences in Treg counts and sensitivity to IL-2 stimulation between MM R and NR, though an excess of Treg over gd T cells has been proposed as a mechanism determining the NR status of MM and other cancer patients (17) . Any role of Treg in this setting is further complicated by the discordant data about their counts and functional status in MM, because both increased numbers of dysfunctional Treg, and normal numbers of immune-competent cells have been reported (46) .
An unexpected finding was PD-L2 downregulation on mDC ZA+ and f-DC ZA+ . Tumor cells and pathogens exploit the PD-1/PD-L pathway to evade host immunity, and several in vitro and in vivo data indicate that downregulation of the PD-1/PD-L pathway may be a profitable way of breaking tolerance and restoring effective Ag-specific immune responses (47) . Most studies have focused on the inhibition of PD-L1 solely by means of blocking Abs. To the best of our knowledge, this is the first report of pharmacological downmodulation of PD-L2 ever reported. Like Treg antagonism, this downregulation was not abrogated by Sim, indicating that ZA has immune modulatory activities not solely dependent on its ability to induce intracellular IPP accumulation and gd T cell proliferation. It has recently been reported that the antiangiogenic activity of ZA can also be independent from its ability to target the Mev pathway (48) .
In conclusion, we have deciphered a virtuous cross-talk between gd T cells, Tregs, DC, and CD8 ab T cells that is fostered by the proliferative activation of gd T cells initiated by the large amounts of IPP generated by ZA-treated mDC and f-DC. Ancillary to IPP generation are the ZA's abilities to antagonize Tregs and downregulate PD-L2 on DC. These ancillary activities are independent from Mev pathway inhibition and gd T cell proliferation. Altogether, these immunomodulatory events can reinstate gd T cell proliferation and upregulate SRV-specific immune responses in MM patients irrespective of their initial NR/R status. These data may help us to further understand the role of gd T cells as cellular bridges between innate and adaptive immunity, and to fine-tune the development of gd T cell-based adoptive immunotherapy strategies in MM and other diseases.
